MA27795A1 - Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant - Google Patents
Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenantInfo
- Publication number
- MA27795A1 MA27795A1 MA28584A MA28584A MA27795A1 MA 27795 A1 MA27795 A1 MA 27795A1 MA 28584 A MA28584 A MA 28584A MA 28584 A MA28584 A MA 28584A MA 27795 A1 MA27795 A1 MA 27795A1
- Authority
- MA
- Morocco
- Prior art keywords
- same
- processes
- pharmaceutical compositions
- compositions containing
- cyclic amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Dérivés d'aminés cycliques, procédés pour leur préparation et compositions pharmaceutiques les contenant Un composé de formule (I) dans laquelle R représente un radical choisi entre les radicaux i) , ii) , iii) et iv) , oé les substituants R1, R2, R3, R4, R5, R6, R7 et les indices m, n et p sont tels que définis dans la description ; ou ses sels et produits de solvatation pharmaceutiquement acceptables ; des procédés pour leur préparation ; des compositions pharmaceutiques les contenant ; et leur utilisation dans le traitement d'affections à médiation par des tachykinines et/ou par inhibition sélective de la protéine transporteur de réabsorption de sérotonine.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0310724.0A GB0310724D0 (en) | 2003-05-09 | 2003-05-09 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27795A1 true MA27795A1 (fr) | 2006-03-01 |
Family
ID=9957781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28584A MA27795A1 (fr) | 2003-05-09 | 2005-11-08 | Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant |
Country Status (21)
Country | Link |
---|---|
US (2) | US20070073061A1 (fr) |
EP (1) | EP1622871A1 (fr) |
JP (1) | JP4684221B2 (fr) |
KR (1) | KR20060009313A (fr) |
CN (1) | CN100534983C (fr) |
AR (1) | AR044269A1 (fr) |
AU (1) | AU2004235967B2 (fr) |
BR (1) | BRPI0410154A (fr) |
CA (1) | CA2524894A1 (fr) |
EG (1) | EG24668A (fr) |
GB (1) | GB0310724D0 (fr) |
IS (1) | IS8164A (fr) |
MA (1) | MA27795A1 (fr) |
MX (1) | MXPA05012096A (fr) |
MY (1) | MY140027A (fr) |
NO (1) | NO20055835L (fr) |
NZ (1) | NZ543068A (fr) |
RU (1) | RU2392270C2 (fr) |
TW (1) | TWI332499B (fr) |
WO (1) | WO2004099143A1 (fr) |
ZA (1) | ZA200508339B (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0412865D0 (en) | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
US7844037B2 (en) | 2005-08-08 | 2010-11-30 | Palm, Inc. | Method and device for enabling message responses to incoming phone calls |
EP2094692B1 (fr) * | 2006-11-01 | 2012-11-28 | Bristol-Myers Squibb Company | Modulateurs du récepteur des glucocorticoïdes et de l'activité ap-1 et/ou nf-kappab et leur utilisation |
EP2331505A2 (fr) * | 2008-09-01 | 2011-06-15 | NeuroSearch A/S | Nouveaux dérivés de piperidine-4-acetamide et utilisation de ceux-ci en tant qu'inhibiteurs du recaptage des neurotransmetteurs monoamines |
ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
CN106187999A (zh) * | 2015-05-04 | 2016-12-07 | 复旦大学 | 取代哌啶类化合物及其制备方法和用途 |
KR20240019754A (ko) | 2021-03-23 | 2024-02-14 | 바이오에이지 랩스, 인코포레이티드 | Nlrp3 인플라마좀의 억제제 |
WO2023147468A1 (fr) | 2022-01-28 | 2023-08-03 | BioAge Labs, Inc. | Inhibiteurs de n-oxyde de l'inflammasome nlrp3 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US309720A (en) * | 1884-12-23 | William p | ||
NL262366A (fr) * | 1960-03-14 | |||
GB1356117A (en) * | 1970-12-16 | 1974-06-12 | Searle & Co | 1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid derivatives |
US5635510A (en) * | 1993-05-06 | 1997-06-03 | Merrell Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines |
DE19603767A1 (de) * | 1996-02-02 | 1997-08-07 | Hoechst Ag | Pyrrolidinpropionsäurederivate mit bradykinin-antagonistischer Wirkung |
US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
WO1999025685A1 (fr) * | 1997-11-18 | 1999-05-27 | Merck & Co., Inc. | Derives de 4-piperidine carboxamides 4-substitues |
US6423519B1 (en) * | 1998-07-15 | 2002-07-23 | Gpc Biotech Inc. | Compositions and methods for inhibiting fungal growth |
CA2443672C (fr) * | 2001-04-12 | 2011-03-29 | Pharmacopeia, Inc. | Aryl et biaryl piperidines utilisees en tant qu'antagonistes de la mch |
JP2005510563A (ja) * | 2001-11-26 | 2005-04-21 | シェーリング コーポレイション | 肥満およびcns障害の処置のためのピペリジン系mchアンタゴニスト |
TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
US20060128752A1 (en) * | 2002-07-03 | 2006-06-15 | Giuseppe Alvaro | Chemical compounds |
-
2003
- 2003-05-09 GB GBGB0310724.0A patent/GB0310724D0/en not_active Ceased
-
2004
- 2004-05-07 MX MXPA05012096A patent/MXPA05012096A/es active IP Right Grant
- 2004-05-07 RU RU2005138315/04A patent/RU2392270C2/ru not_active IP Right Cessation
- 2004-05-07 TW TW093112840A patent/TWI332499B/zh not_active IP Right Cessation
- 2004-05-07 NZ NZ543068A patent/NZ543068A/xx unknown
- 2004-05-07 BR BRPI0410154-5A patent/BRPI0410154A/pt not_active IP Right Cessation
- 2004-05-07 JP JP2006505412A patent/JP4684221B2/ja not_active Expired - Fee Related
- 2004-05-07 EP EP04731635A patent/EP1622871A1/fr not_active Withdrawn
- 2004-05-07 AU AU2004235967A patent/AU2004235967B2/en not_active Ceased
- 2004-05-07 CA CA002524894A patent/CA2524894A1/fr not_active Abandoned
- 2004-05-07 AR ARP040101565A patent/AR044269A1/es not_active Application Discontinuation
- 2004-05-07 MY MYPI20041688A patent/MY140027A/en unknown
- 2004-05-07 CN CNB2004800194957A patent/CN100534983C/zh not_active Expired - Fee Related
- 2004-05-07 KR KR1020057021196A patent/KR20060009313A/ko active IP Right Grant
- 2004-05-07 WO PCT/EP2004/005005 patent/WO2004099143A1/fr active Application Filing
- 2004-05-07 US US10/554,822 patent/US20070073061A1/en not_active Abandoned
-
2005
- 2005-10-14 ZA ZA200508339A patent/ZA200508339B/en unknown
- 2005-10-29 EG EGNA2005000691 patent/EG24668A/xx active
- 2005-11-08 MA MA28584A patent/MA27795A1/fr unknown
- 2005-12-01 IS IS8164A patent/IS8164A/is unknown
- 2005-12-08 NO NO20055835A patent/NO20055835L/no unknown
-
2007
- 2007-10-10 US US11/869,945 patent/US20090192194A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EG24668A (en) | 2010-04-11 |
EP1622871A1 (fr) | 2006-02-08 |
US20090192194A1 (en) | 2009-07-30 |
AU2004235967A1 (en) | 2004-11-18 |
BRPI0410154A (pt) | 2006-05-16 |
MXPA05012096A (es) | 2006-02-08 |
TW200510309A (en) | 2005-03-16 |
RU2005138315A (ru) | 2007-06-20 |
RU2392270C2 (ru) | 2010-06-20 |
KR20060009313A (ko) | 2006-01-31 |
US20070073061A1 (en) | 2007-03-29 |
WO2004099143A1 (fr) | 2004-11-18 |
ZA200508339B (en) | 2006-10-25 |
JP4684221B2 (ja) | 2011-05-18 |
GB0310724D0 (en) | 2003-06-11 |
JP2006525975A (ja) | 2006-11-16 |
MY140027A (en) | 2009-11-30 |
AR044269A1 (es) | 2005-09-07 |
NZ543068A (en) | 2009-07-31 |
CN1819995A (zh) | 2006-08-16 |
CN100534983C (zh) | 2009-09-02 |
NO20055835L (no) | 2006-02-07 |
AU2004235967B2 (en) | 2008-10-23 |
IS8164A (is) | 2005-12-01 |
TWI332499B (en) | 2010-11-01 |
NO20055835D0 (no) | 2005-12-08 |
CA2524894A1 (fr) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27795A1 (fr) | Derives d'amine cycliques, procedes de preparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA26877A1 (fr) | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
HUP0301690A2 (hu) | Szinergikus eljárások és készítmények rák kezelésére | |
MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
MA28094A1 (fr) | Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
HUP0303494A2 (hu) | Bakteriális giráz inhibitorokat tartalmazó gyógyszerkészítmények és alkalmazásaik | |
MA27764A1 (fr) | Acides carboxyliques alpha-substitués servant de modulateurs de PPAR | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
SE0104332D0 (sv) | Therapeutic agents | |
TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
MY138906A (en) | Phenyl derivatives as ppar agonists | |
MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
MA27775A1 (fr) | Composes organiques | |
HRP20040824B1 (hr) | Derivati aminoindazola, postupak i međuprodukti dobiveni prilikom pripravljanja medicinskih produkata, te farmaceutski pripravci koji ih sadrže | |
AR033594A1 (es) | Un compuesto derivado de 3-aroilindol, su utilizacion, procedimientos para prepararlo, una composicion farmaceutica que lo contiene, un medicamento constituido por dicho compuesto, y compuestos intermediarios | |
MA27716A1 (fr) | 4-aminopyrimidine-5-one | |
DE60305484D1 (de) | Verbindungen und deren verwendung als 5-ht inhibitore | |
TNSN98083A1 (fr) | Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
HUP0203054A2 (hu) | Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0500201A2 (hu) | Policiklusos vegyületek, mint potenciális alfa2-adrenoceptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
TNSN98151A1 (fr) | Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole. | |
ATE482933T1 (de) | Sulfopyrrolderivate | |
KR970706826A (ko) | 포스포디에스테라제 IV 억제제로서의 디아제피노-인돌(Diazepino-Indoles as Phosphodiesterase Ⅳ Inhibitors) |